Konstantin A Petrov
Overview
Explore the profile of Konstantin A Petrov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrova A, Nguyen H, Zueva I, Petrov K, Lobov A, Kazakova O
Molecules
. 2025 Jan;
30(1.
PMID: 39795152
Alzheimer's disease (AD) poses a significant public health issue. Despite the fact that today there are several methods of maintenance therapy, one of the most widely used methods is designed...
2.
Kushnazarova R, Mirgorodskaya A, Vasilieva E, Lenina O, Petrov K, Zakharova L
Pest Manag Sci
. 2024 Jul;
80(11):5965-5973.
PMID: 39034816
Background: Surfactants, particularly non-ionic ones, are widely used as adjuvants in pesticide formulations due to their ability to maintain pesticide effectiveness without changing solution properties, such as pH. While non-ionic...
3.
Zueva I, Vasilieva E, Gaynanova G, Moiseenko A, Burtseva A, Boyko K, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003588
A central event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of senile plaques composed of aggregated amyloid-β (Aβ) peptides. The main class of drugs currently used for...
4.
Shulaeva M, Zueva I, Nikolaev A, Saifina L, Sharafutdinova D, Babaev V, et al.
Bioorg Chem
. 2023 Sep;
141:106858.
PMID: 37774432
A series of new uncharged conjugates of adenine, 3,6-dimetyl-, 1,6-dimethyl- and 6-methyluracil with 1,2,4-triazole-3-hydroxamic and 1,2,3-triazole-4-hydroxamic acid moieties were synthesized and studied as reactivators of organophosphate-inhibited cholinesterase. It is shown...
5.
Muravev A, Voloshina A, Sapunova A, Gabdrakhmanova F, Lenina O, Petrov K, et al.
Bioorg Chem
. 2023 Jul;
139:106742.
PMID: 37480816
Tumor selectivity is yet a challenge in chemotherapy-based cancer treatment. A series of calixarenes derivatized at the lower rim with 3-phenyl-1H-pyrazole units with variable upper-rim substituent and conformations of macrocyclic...
6.
Gorin B, Tukhovskaya E, Ismailova A, Slashcheva G, Lenina O, Petrov K, et al.
Front Pharmacol
. 2023 Mar;
14:1091858.
PMID: 36909182
Pharmacokinetic characteristics as well as cognitive-enhancing nootropic activity of latrepirdine (Dimebon) in relationship with its polymorphic forms have been studied in SD and Wistar rats. The pharmacokinetics of six polymorphs...
7.
Vasilieva E, Kuznetsova D, Valeeva F, Kuznetsov D, Zakharov A, Amerhanova S, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559339
Chitosan-decorated liposomes were proposed for the first time for the intranasal delivery of acetylcholinesterase (AChE) reactivator pralidoxime chloride (2-PAM) to the brain as a therapy for organophosphorus compounds (OPs) poisoning....
8.
Saifina L, Abdalla M, Gubaidullina L, Zueva I, Eltayb W, El-Arabey A, et al.
Eur J Med Chem
. 2022 Dec;
246:114949.
PMID: 36462442
A series of new compounds in which uracil and 3,6-dimethyluracil moieties are bridged with different spacers were prepared and evaluated in vitro for the acetyl- and butyrylcholinesterase (AChE and BChE)...
9.
Semenov V, Zueva I, Lushchekina S, Suleimanov E, Gubaidullina L, Shulaeva M, et al.
Molecules
. 2022 Nov;
27(22).
PMID: 36431954
Novel derivatives based on 6-methyluracil and condensed uracil, 2,4-quinazoline-2,4-dione, were synthesized with terminal - and -benzoate moieties in polymethylene chains at the N atoms of the pyrimidine ring. In the...
10.
Kuznetsova D, Gaynanova G, Vasilieva E, Pavlov R, Zueva I, Babaev V, et al.
Pharmaceutics
. 2022 Sep;
14(9).
PMID: 36145698
One of the main problems in the treatment of poisoning with organophosphorus (OPs) inhibitors of acetylcholinesterase (AChE) is low ability of existing reactivators of AChE that are used as antidotes...